Table 3.
Effects of demographic characteristics on T1 or T2 of the 115 COVID-19 patients.
| Variables | n (%) | T1(d) |
T1(d) |
||
|---|---|---|---|---|---|
| Mean ± SD | P | Mean ± SD | P | ||
| Age cut-off mean (y) <60 ≥60 |
48 (41.7) 67 (58.3) |
28.0 ± 8.2 28.7 ± 8.8 |
0.718 | 32.4 ± 8.3 32.6 ± 9.1 |
0.869 |
| Sex male female |
61 (53.0) 54 (47.0) |
30.1 ± 7.7 26.5 ± 9.1 |
0.022 | 34.5 ± 7.7 30.3 ± 9.2 |
0.010 |
| Fever yes No |
93 (80.9) 22 (19.1) |
27.0 ± 8.3 34.5 ± 7.0 |
0.000 | 31.1 ± 8.5 38.5 ± 7.3 |
0.000 |
| Comorbidities none Group Ⅰ Group Ⅱ GroupⅢ Group Ⅵ Group Ⅰ+GroupⅢ Group Ⅱ+GroupⅢ |
42 (36.5) 23 (20.0) 22 (19.1) 11 (9.6) 17 (14.8) 34 (30.0) 33 (28.7) |
26.9 ± 7.3 28.5 ± 10.5 30.0 ± 7.6 32.2 ± 10.0 27.6 ± 8.5 29.7 ± 10.3 30.7 ± 8.4 |
0.516a 0.124a 0.055a 0.739a 0.188a 0.040a |
30.9 ± 7.2 32.7 ± 10.6 34.5 ± 8.4 36.3 ± 10.2 31.4 ± 8.7 33.8 ± 10.4 35.1 ± 8.9 |
0.480a 0.080a 0.049a 0.809a 0.169a 0.028a |
| Severity of the disease common severe critical |
6 (5.2) 101 (87.8) 8 (7.0) |
28.8 ± 10.6 28.7 ± 8.7 20.5 ± 7.5 |
0.040Δ | 33.2 ± 10.6 32.9 ± 8.8 25.0 ± 6.8 |
0.054Δ |
| Antiviral therapy arbidol lopinavir/ritonavir others none |
63 (54.8) 43 (37.4) 5 (4.3) 4 (3.5) |
26.9 ± 6.9 31.3 ± 9.5 29.0 ± 23.2 20.8 ± 7.3 |
0.008b | 31.0 ± 6.9 35.3 ± 9.9 33.2 ± 13.4 25.3 ± 7.6 |
0.013b |
| Antibiotic therapy one two or more none |
59 (51.3) 16 (13.9) 40 (34.8) |
28.7 ± 8.8 29.9 ± 10.0 27.5 ± 7.5 |
0.598Δ | 32.9 ± 9.0 33.4 ± 10.6 31.5 ± 7.5 |
0.693Δ |
| Use Chinese patent medi- cine or herbal medicine yes No |
105 (91.3) 10 (8.7) |
29.0 ± 8.6 22.2 ± 3.9 |
0.000 | 26.7 ± 3.8 33.1 ± 8.9 |
0.000 |
| Corticosteroid therapy yes No |
14 (12.2) 101 (87.8) |
24.3 ± 6.5 29.0 ± 8.7 |
0.053 | 27.9 ± 6.4 33.1 ± 8.8 |
0.035 |
| Grades of lung lesions on chest CT Ⅰ Ⅱ Ⅲ Ⅳ |
34 (29.6) 29 (25.2) 32 (27.8) 20 (17.4) |
27.2 ± 9.4 30.2 ± 8.7 28.1 ± 8.5 28.4 ± 8.5 |
0.586Δ | 31.4 ± 9.4 34.1 ± 9.0 32.4 ± 8.9 32.3 ± 7.0 |
0.681Δ |
ΔAmong groups.
a
vs none.
b
arbidol vs lopinavir/ritonavir.